 |
Indication & Dosage |
| |
| |
| Oral |
| SHORT-TERM MANAGEMENT OF INSOMNIA |
Adult:
7.5 mg at bedtime.
Elderly: Initially, 3.75 mg at bedtime. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Hepatic and renal insufficiency; elderly; psychiatric disorders; history of drug abuse. May impair ability to drive or operate machinery. Limit treatment duration to < 4 wk to minimise risk of dependence and tolerance. Avoid abrupt discontinuation of therapy. |
| |
|
| Adverse Drug Reactions |
Metallic or bitter aftertaste; irritability, confusion, depressed mood, aggressiveness, incoordination, anterograde amnesia, mild increase in LFT, drowsiness, lightheadedness, nausea, vomiting, urticaria, rashes. |
| |
|
| Interactions |
Reduced hypnotic effect with phenytoin and carbamazepine. Increased drowsiness and incoordination with TCA. Increased CNS depressant effect with alcohol and other CNS depressants. Decreased zopiclone concentration with rifampicin. Possible increase in zopiclone concentration with CYP 3A4 inhibitors e.g. erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir. Possible decrease in zopiclone with St John's Wort. |
| |
|
|
|
